ArticlePloS one2025
AD-GCN: A novel graph convolutional network integrating multi-omics data for enhanced Alzheimer's disease diagnosis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- From molecules to minds: Integrative multi-omics in psychiatry.Journal of mood and anxiety disorders · 2026Review
- Protein glycoxidation in neuropsychiatric disorders-from basic research to clinical practice.Redox biology · 2026Review
- Exposome influences: a multi-omics perspective on the combined toxic effects of pharmaceuticals and personal care products in Alzheimer's disease.Frontiers in toxicology · 2026Review
- DEG-BRIN-GCN: interpretable graph convolutional framework with differentially expressed genes brain region interaction network prior for AD diagnosis.Frontiers in neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) etiology is complex, influenced by demographic risk factors such as age, sex, and educational level, alongside multi-omics factors derived from genomics, transcriptomics, and epigenomics. Advancements in multi-omics technology present both challenges and opportunities for AD diagnosis, enabling a more comprehensive understanding of the complex interactions among contributing factors, with the goal of improving diagnostic accuracy. To address this challenge, we propose a novel feature fusion approach in this study, AD-GCN, which integrates multi-omics data and their interaction networks to achieve more precise diagnosis and analysis of AD. In this study, we applied polygenic risk score and random forest algorithms for feature selection on genetic variation and methylation data. We then developed an AD-GCN for both multi-omics and single-omics classification tasks and compared its performance with that of machine learning ensemble methods. The experimental results demonstrated that multi-omics classification significantly outperformed single-omics classification, with AD-GCN surpassing the machine-learning ensembles. These findings highlight AD-GCN's strong potential to enhance AD diagnosis and improve accuracy in differentiating disease stages by integrating interactions across omics data, laying a solid foundation for the development of more precise and personalized AD diagnostic models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.